Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an announcement.
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing share buy-back program. As of the latest notification, the company has repurchased a total of 3,871,192 securities, with an additional 36,568 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological conditions. The company is known for its work in creating treatments aimed at improving the quality of life for patients with neurodevelopmental and neurodegenerative disorders.
YTD Price Performance: 10.08%
Average Trading Volume: 723,364
Technical Sentiment Signal: Buy
Current Market Cap: A$1.74B
For an in-depth examination of NEU stock, go to TipRanks’ Stock Analysis page.